Momenta Pharmaceuticals Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Momenta Pharmaceuticals Inc.

An SI Board Since March 2004

Posts	SubjectMarks	Bans	Symbol
3027	64	0	MNTA

Emcee: michael_f_murphy	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
627	tim anderson, pru 2/12/07: EARNINGS PREVIEW: SNY Q4 • SNY is scheduled to repor	software salesperson	-	2/12/2007
626	It's gone. Check your email. Jon	Robohogs	-	2/12/2007
625	At one point my screen showed 3.2M shares traded then dropped back to 1.8M. Eve	IRWIN JAMES FRANKEL	-	2/12/2007
624	1.4 million share block just went off in 15.50 area. Jon	Robohogs	-	2/12/2007
623	Some more speculation... < We think that it was the fear of a reduced market	dr.praveen	-	2/12/2007
622	5 days to option expiration. Let's see if this week can come close to be be	Rocky9	-	2/11/2007
621	I think thats the argument mnta will make, greater consistency and qc than the i	rkrw	-	2/11/2007
620	>what would be interesting would be trying to figure out which of the many di	technetium	-	2/11/2007
619	The real problem as I see it is that you perfectly copy one batch and then SNY t	Robohogs	-	2/11/2007
618	agree but wouldnt the muscle of novartis count for something ?	dalroi	-	2/11/2007
617	Guess everyone is waiting for Jim Cramer to open his mouth and straighten this m	D.Lu	-	2/11/2007
616	<i>I would think the very variability of Lovenox between batches should ma	DewDiligence_on_SI	-	2/11/2007
615	I find it very interesting that SNY makes the argument that the variability in L	Robohogs	-	2/10/2007
614	Some aventis arguments v mnta in a CP but before mnta had even filed. Page 17-20	rkrw	-	2/10/2007
613	UBS has a financial interest in the fight, but at least their analyst admits tha	Arthur Radley	-	2/10/2007
612	That's correct. Graham Parry works out of Merrill UK and covers pharmaceutic	tom pope	-	2/10/2007
611	Boston Globe Momenta wins in court. In an interview yesterday, Momenta chief ex	Go Market Go!	-	2/10/2007
610	Yeah, that's basically what I'm asking.... how could the Merrill analy	scaram(o)uche	-	2/10/2007
609	"framing an argument against someone who knows more about the lovenox struc	Go Market Go!	-	2/10/2007
608	I'm sure the ML analyst covers Sanofi and has an investment banking relation	rkrw	-	2/10/2007
607	Ann Pharmacother. 2004 Apr;38(4):563-8. Epub 2004 Feb 24. Variability of plasma	scaram(o)uche	-	2/10/2007
606	>> as Momenta attempts to more fully characterize Lovenox, we continue to	scaram(o)uche	-	2/10/2007
605	Lovenox is a heterogeneous mixture with lot-to-lot variation, no? Pig intestine	scaram(o)uche	-	2/10/2007
604	The market thinks the FDA will be slow to approve a generic, plus Sanofi is fili	technetium	-	2/10/2007
603	What if the FDA only wanted MNTA's drug and not Teva or Amph. What could hap	Go Market Go!	-	2/10/2007

Go to reply# or date (mm/dd/yy):